MGC Pharmaceuticals Ltd (ASX: MXC) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

MGC Pharmaceuticals Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $96.91 million
P/E Ratio N/A
Dividend Yield N/A
Shares Outstanding 2.42 billion
Earnings per share -0.008
Dividend per share N/A
Year To Date Return 60.00%
Earnings Yield N/A
Franking N/A
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

Should you invest $1,000 in right now?

Before you consider , you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

MGC Pharmaceuticals Ltd (ASX: MXC)
Latest News

MXC ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
YesNo

About MGC Pharmaceuticals Ltd

MGC Pharmaceuticals Ltd is a biopharma company with a Nature to Medicine strategy at the forefront of the emerging phytocannabinoid and plant derived medicine markets. The company's mission is to build an innovative, global bio-pharma company providing standardised, affordable plant derived medicines of the highest regulatory compliance for targeted global markets.

MXC Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
03 Dec 2021 $0.04 $0.00 0.00% 727,681 $0.04 $0.04 $0.04
02 Dec 2021 $0.04 $0.00 0.00% 5,679,290 $0.04 $0.04 $0.04
01 Dec 2021 $0.04 $0.00 0.00% 1,899,694 $0.04 $0.04 $0.04
29 Nov 2021 $0.04 $0.00 0.00% 2,614,882 $0.04 $0.04 $0.04
26 Nov 2021 $0.04 $0.00 0.00% 990,093 $0.04 $0.05 $0.04
25 Nov 2021 $0.05 $0.00 0.00% 1,059,136 $0.04 $0.05 $0.04
24 Nov 2021 $0.05 $0.00 0.00% 2,068,229 $0.05 $0.05 $0.04
23 Nov 2021 $0.05 $0.00 0.00% 2,388,132 $0.05 $0.05 $0.04
22 Nov 2021 $0.05 $0.00 0.00% 6,958,377 $0.05 $0.05 $0.04
19 Nov 2021 $0.05 $0.00 0.00% 1,523,959 $0.05 $0.05 $0.05
18 Nov 2021 $0.05 $0.00 0.00% 1,362,166 $0.05 $0.05 $0.05
17 Nov 2021 $0.05 $0.00 0.00% 1,366,962 $0.05 $0.05 $0.05
16 Nov 2021 $0.05 $0.00 0.00% 3,695,958 $0.05 $0.05 $0.05
15 Nov 2021 $0.05 $0.00 0.00% 970,817 $0.05 $0.05 $0.05
12 Nov 2021 $0.05 $0.00 0.00% 2,925,856 $0.05 $0.05 $0.05
11 Nov 2021 $0.05 $0.00 0.00% 3,911,773 $0.05 $0.05 $0.05
10 Nov 2021 $0.05 $0.00 0.00% 2,104,590 $0.05 $0.05 $0.05
09 Nov 2021 $0.05 $0.00 0.00% 6,425,864 $0.05 $0.05 $0.05
08 Nov 2021 $0.05 $0.00 0.00% 3,615,471 $0.05 $0.05 $0.05

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
24 Nov 2021 Ross Walker Exercise 600 $27,000
Conversion of securities. 1,500,000 - Performance Rights
24 Nov 2021 Ross Walker Buy 600 $27,000
Conversion of securities.
07 Oct 2021 Stephen Parker Exercise 600 $35,400
Conversion of securities. 2,000,000 - Performance Rights
07 Oct 2021 Stephen Parker Buy 600 $35,400
Conversion of securities.
30 Sep 2021 Evan Hayes Buy 295 $17,655
On-market trade.
09 Sep 2021 Roby Zomer Issued 27 $1,644,000
Issue of securities. 32,400,000 - Performance Rights
09 Sep 2021 Evan Hayes Issued 2 $156,000
Issue of securities. 2,600,000 - Performance Rights
09 Sep 2021 Stephen Parker Issued 2 $156,000
Issue of securities. 2,600,000
09 Sep 2021 Nativ Segev Issued 2 $126,000
Issue of securities. 2,100,000 - Performance Rights
09 Sep 2021 Brett Mitchell Expiry 5 $300,000
Options expired.
09 Sep 2021 Brett Mitchell Buy 555 $24,999
Exercise of options.
09 Sep 2021 Brett Mitchell Issued 27 $1,644,000
Issue of securities. 32,400,000 - Performance Rights
09 Sep 2021 Brett Mitchell Exercise 555 $24,999
Exercise of options.
09 Sep 2021 Ross Walker Issued 2 $126,000
Issue of securities. 2,100,000 - Performance Rights
09 Sep 2021 Ross Walker Expiry 185 $11,111
Options expired.
05 Mar 2021 Roby Zomer Cancelled 2 $165,000
Cancellation of securities. 5,000,000 - Performance Rights
05 Mar 2021 Stephen Parker Buy 282 $9,999
On-market trade. Trading in GBP.
05 Mar 2021 Brett Mitchell Cancelled 2 $165,000
Cancellation of securities. 5,000,000 - Performance Rights

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Mr Evan Hayes Non-Executive Director Sep 2020
Mr Hayes is an experienced Board member and brings over 20+ commercial and leadership experience within the healthcare and biotechnology sectors. Mr Hayes is currently the Asia Pacific Managing Director of Factors Group. Prior to this Mr Hayes was the Director of Sourcing and Product development, Blackmores, leading the Procurement, Technical, New product development, and Strategic sourcing divisions. Evan has served on multiple boards, worked in Europe the USA and in Australia and has knowledge of both the FDA and the TGA. Mr Hayes is an author of multiple patents including one world patent. He is a member of the Risk committee.
Mr Brett Anthony Mitchell Executive ChairmanExecutive Director Apr 2013
Mr Mitchell has over 25 years of experience in the venture capital, equity capital markets, technology and resources sectors. He has been involved in the founding, financing and management of both private and publicly listed companies, and was instrumental in the successful LSE listing for MGC Pharma in February 2021. Mr Mitchell is a founder and director of Chieftain Securities Pty Ltd, a Perth based Corporate Advisory & Venture Capital firm and founder and shareholder of Graft Polymer (UK) Ltd. Mr Mitchell is also currently Non-Executive Director of ASX Listed company Red Dirt Metals Limited (RDT), and Executive Chairman of an Australian unlisted public company, Australian Cannabis Ventures Limited. He is a member of the Risk committee.
Dr Ross Grant Thomas Walker Non-Executive Director Feb 2016
Dr Walker has over 35 years of experience as a clinician. For the past 20 years, he has been focusing on preventative cardiology. He is the author of seven books and a health presenter in the Australian Media. He is a member of the Risk committee.
Mr Nativ Segev Non-Executive Director Feb 2016
Mr Segev has over 10 years of experience in implementation, legislation and lobbying in the global Medical Cannabis industry, combined with over 15 years of experience in diverse executive roles.
Mr Roby Reuven Zomer Chief Executive OfficerManaging Director Feb 2016
Mr Zomer have ten years of experience in projects in the Biotech and Agrotech sectors. Over the past year, Mr Zomer has been in to solidifying the company's standing as a provider of phytomedicines in the regions globally and has launched a product, ArtemiCTM, which is from initial results proving an treatment against symptoms of COVID-19, backed by ongoing clinical trials. Additionally, he has put his engineering and medical background into play, and has put a emphasis on the company's research and development activities, and to led to possibilities of distribution and collaboration in markets around the globe.
Mr Stephen Barry Parker Non-Executive Director Mar 2019
Dr Parker has over thirty years of experience in the pharmaceuticals and biotechnology sectors, as a senior executive in the sector, a strategic consultant, a venture capitalist and a senior corporate financier with Baring's, Warburg's and Apax Partners. Dr Parker is currently Chairman of Sareum Holdings plc and a non-Executive Director of Eternans Limited. He is Chair of the Corporate Governance committee and a member of the Risk committee.
Mr David Lim Joint Company Secretary Jun 2021
-
Mrs Rachel Kerr Joint Company Secretary Feb 2019
-
Nicole Godresse Global Chief Sales Officer
-
David Lim Joint Company Secretary
-
Rachel Kerr Joint Company Secretary
-

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
Computershare Clearing Pty Ltd <Ccnl Di A/C> 861,191,552 36.10%
HSBC Custody Nominees (Australia) Limited 115,831,701 4.86%
Citicorp Nominees Pty Limited 41,376,298 1.73%
Mr George Bishay 36,822,890 1.54%
Mercer Street Global Opportunity Fund Llc 34,300,000 1.44%
BNP Paribas Nominees Pty Ltd ACF Clearstream 27,835,388 1.17%
BNP Paribas Noms Pty Ltd <Drp> 24,814,099 1.04%
BNP Paribas Nominees Pty Ltd Six Sis Ltd <DRP A/C> 19,191,067 0.80%
Mr Brett Mitchell + Mrs Michelle Mitchell <Mitchell Spring Family A/C> 17,156,249 0.72%
Cannvalate Pty Ltd 15,151,515 0.64%
The Trust Company (Australia) Limited <Mof A/C> 12,500,000 0.52%
Chetcuti Holdings Pty Ltd 12,000,000 0.50%
Surfit Capital Pty Ltd 11,500,000 0.48%
Merrill Lynch (Australia) Nominees Pty Limited 11,179,778 0.47%
Cs Fourth Nominees Pty Limited <HSBC Cust Nom Au Ltd 11 A/C> 8,651,535 0.36%
Mr Brett Mitchell + Mrs Michelle Mitchell <Lefthanders Super Fund A/C> 8,418,337 0.35%
Fadco Investments Limited 6,772,613 0.28%
Andoryka Holdings Pty Ltd <Wareing Superannuation A/C> 6,166,666 0.26%
Dr Jonathan Grunfeld 6,090,909 0.26%
J & D Peos Super Pty Ltd <J & D Peos Super Fund A/C> 5,585,262 0.23%

Profile

since

Note